Clinical trial
A Double Blind Randomized Controlled Crossover Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe Postural Orthostatic Tachycardia Syndrome
NCT03365414 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double Blind Randomized Controlled Crossover Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe Postural Orthostatic Tachycardia Syndrome
- Lead sponsor
- University of Alberta
- Phase
- Phase 3
- Overall status
- Withdrawn
- Start date
- January 31, 2022
- Completion date
- March 31, 2024
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.